Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer.

Anderson RA, Wallace WH.

Fertil Steril. 2013 May;99(6):1469-75. doi: 10.1016/j.fertnstert.2013.03.014. Epub 2013 Mar 27. Review.

PMID:
23541317
2.

Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors.

Lunsford AJ, Whelan K, McCormick K, McLaren JF.

Fertil Steril. 2014 Jan;101(1):227-31. doi: 10.1016/j.fertnstert.2013.08.052. Epub 2013 Sep 29.

PMID:
24083876
3.

Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone.

Toner JP, Seifer DB.

Fertil Steril. 2013 Jun;99(7):1825-30. doi: 10.1016/j.fertnstert.2013.03.001. Epub 2013 Mar 30. Review.

PMID:
23548941
4.

Tests for ovarian reserve: reliability and utility.

Domingues TS, Rocha AM, Serafini PC.

Curr Opin Obstet Gynecol. 2010 Aug;22(4):271-6. doi: 10.1097/GCO.0b013e32833b4f5c. Review.

PMID:
20543692
5.

Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications.

Broer SL, Broekmans FJ, Laven JS, Fauser BC.

Hum Reprod Update. 2014 Sep-Oct;20(5):688-701. doi: 10.1093/humupd/dmu020. Epub 2014 May 12. Review.

6.

Impact of cancer therapies on ovarian reserve.

Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, Vance A, Ginsberg JP.

Fertil Steril. 2012 Jan;97(1):134-40.e1. doi: 10.1016/j.fertnstert.2011.10.040. Epub 2011 Dec 2.

7.

Anti-Müllerian hormone: clairvoyance or crystal clear?

Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A.

Hum Reprod. 2012 Mar;27(3):631-6. doi: 10.1093/humrep/der446. Epub 2012 Jan 11.

8.

Age at menarche: a predictor of diminished ovarian function?

Weghofer A, Kim A, Barad DH, Gleicher N.

Fertil Steril. 2013 Oct;100(4):1039-43. doi: 10.1016/j.fertnstert.2013.05.042. Epub 2013 Jun 27.

PMID:
23809497
9.

Assessment of FSHR variants and antimüllerian hormone in infertility patients with a reduced ovarian response to gonadotropin stimulation.

Binder H, Strick R, Zaherdoust O, Dittrich R, Hamori M, Beckmann MW, Oppelt PG.

Fertil Steril. 2012 May;97(5):1169-75.e1. doi: 10.1016/j.fertnstert.2012.02.012. Epub 2012 Mar 7.

PMID:
22401810
10.

Ovarian reserve in young women of reproductive age with Crohn's disease.

Fréour T, Miossec C, Bach-Ngohou K, Dejoie T, Flamant M, Maillard O, Denis MG, Barriere P, Bruley des Varannes S, Bourreille A, Masson D.

Inflamm Bowel Dis. 2012 Aug;18(8):1515-22. doi: 10.1002/ibd.21872. Epub 2011 Sep 20.

PMID:
21936034
11.

Impact of physical activity on ovarian reserve markers in normal, overweight and obese reproductive age women.

Surekha T, Himabindu Y, Sriharibabu M, Pandey AK.

Indian J Physiol Pharmacol. 2014 Apr-Jun;58(2):162-5.

PMID:
25509968
12.

Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles.

Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS.

Reprod Biol Endocrinol. 2009 Sep 17;7:100. doi: 10.1186/1477-7827-7-100.

13.

The role of anti-Müllerian hormone in female fertility and infertility - an overview.

Grynnerup AG, Lindhard A, Sørensen S.

Acta Obstet Gynecol Scand. 2012 Nov;91(11):1252-60. doi: 10.1111/j.1600-0412.2012.01471.x. Review.

PMID:
22646322
14.

[Statement: cancer treatments and ovarian reserve].

Basille C, Torre A, Grynberg M, Gallot V, Frydman R, Fanchin R.

J Gynecol Obstet Biol Reprod (Paris). 2010 Oct;39(6):433-43. doi: 10.1016/j.jgyn.2010.05.012. Epub 2010 Jul 31. Review. French.

15.

Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing.

Lutchman Singh K, Davies M, Chatterjee R.

Hum Reprod Update. 2005 Jan-Feb;11(1):69-89. Epub 2004 Nov 29. Review.

16.

Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone.

Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP, de Jong FH, van den Heuvel-Eibrink MM.

Hum Reprod. 2009 Apr;24(4):982-90. doi: 10.1093/humrep/den487. Epub 2009 Jan 18.

17.

A new approach to ovarian reserve testing.

Sun W, Stegmann BJ, Henne M, Catherino WH, Segars JH.

Fertil Steril. 2008 Dec;90(6):2196-202. doi: 10.1016/j.fertnstert.2007.10.080. Epub 2008 Apr 22. Review.

18.

Association of abnormal ovarian reserve parameters with a higher incidence of aneuploid blastocysts.

Katz-Jaffe MG, Surrey ES, Minjarez DA, Gustofson RL, Stevens JM, Schoolcraft WB.

Obstet Gynecol. 2013 Jan;121(1):71-7. doi: http://10.1097/AOG.0b013e318278eeda.

PMID:
23262930
19.

Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve.

Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H.

Fertil Steril. 2011 Jun;95(7):2364-8. doi: 10.1016/j.fertnstert.2011.03.081. Epub 2011 May 6.

PMID:
21529798
20.

Utility of antimüllerian hormone level obtained for infertility assessment for alerting to ovarian tumor.

Hill BJ, Morrell TJ, Zhang MM, Norian JM.

Obstet Gynecol. 2013 Feb;121(2 Pt 2 Suppl 1):454-7. doi: http://10.1097/AOG.0b013e31827d8ff3.

PMID:
23344407
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk